Sekundær leukæmi er blevet indberettet for patienter, der fik langtidsbehandling med hydroxycarbamid for myeloproliferative sygdomme.
In patients receiving long-term hydroxycarbamide for myeloproliferative disorders, secondary leukaemia has been reported.